According to the data presented at the AACR 2024 conference, as of the data cutoff date of June 12, 2023, a total of 8 patients at a median age of 11 years diagnosed with inflammatory myofibroblast...
Glutathione S‑transferase Pi (GSTP) has a role in detoxification and anti‑oxidative damage response. Additionally, GSTP has a chaperone function that regulates key oncogenic pathways such as the KRAS and JNK. Since redundant pathways could compensate for the inhibition of a single kinase, targeting multiple pathway...
Find More
The Medical Tourism market has emerged as a dynamic sector in recent years, experiencing significant evolution driven by a myriad of factors. Traditionally, Medical Tourism referred to the practice of traveling abroad for medical treatment, often sought due to cost considerations, access to advanced technologies, o...
Find More
Adagrasib is an irreversible KRAS G12C inhibitor that is designed to have a 23-hour half-life, dose-dependent pharmacokinetics, and central nervous system penetration. The pooled analysis of Phase I/II (KRYSTAL-1) trial that was presented during the AACR 2024 conference demonstrated that, as of the data cutoff date...
Find More
Renal cell carcinoma (RCC) is the most common type of kidney cancer, characterized by various subtypes like clear cell, papillary, chromophore, and collecting duct carcinomas. Clear cell carcinoma, constituting 80% of all RCC cases commands the majority of treatment focus due to its predominance. Currently, the ...
Find More
Overexpression of TROP2 (trophoblast cell surface antigen 2) in advanced gastric cancer has been identified as a poor prognostic factor. SKB264 (MK-2870) is a TROP2 ADC (Antibody-Drug Conjugate) designed with a unique linker to attach the payload, a belotecan-derivative topoisomerase I inhibitor. This linker underg...
Find More
ASTX295 is a novel small molecule antagonist of human Murine Double Minute 2 (MDM2), which tightly regulates the level and activity of the p53 tumor suppressor. According to the data presented at the AACR 2024 conference, the study enrolled 83 participants across 14 cohorts, investigating various dosing regimens an...
Find More
Triple-negative breast cancer (TNBC) accounts for 15–20% of incident breast cancers and is the only breast cancer (BC) subtype lacking targeted treatments. It is a biologically aggressive tumor characterized by moderate/high grade and highly proliferative cancer cells, which, together with limited treatment options...
Find More
At the American Association for Cancer Research (AACR) Annual Meeting 2024, significant findings from the Phase I/II PETRA trial, led by researchers at The University of Texas MD Anderson Cancer Center, were presented. The trial focused on evaluating the first-in-class PARP1-selective inhibitor, saruparib, in patie...
Find More
P-BCMA-ALLO1 is a novel investigational BCMA-targeted allogeneic, T stem cell memory (TSCM)-rich chimeric antigen receptor T-cell (CAR-T) therapy manufactured from healthy donor T-cells and available off-the-shelf. The findings presented at the AACR 2024 demonstrated that around 60% of patients (3 out of 5) with RR...
Find More
Over the years, the Oncology domain has experienced the entry of several treatment approaches. Thera.....
Find More
COVID-19 transforms healthcare facets at an unprecedented pace. Based on emerging technology, we can.....
Find More
Retinitis pigmentosa is a gradual deterioration of the ability of eyes to see. The defect in the eye.....
Find More
Immunity is a major concern in the present times, and consumers have increased their focus on boosti.....
Find More
Blastic plasmacytoid dendritic cell neoplasm (BPDCN), an extremely rare form of neoplasm, generally .....
Find More
Vascular Dementia (VaD) is a common type of Dementia caused by reduced blood flow to the brain. VaD .....
Find More-Agonist.png "Toll-like Receptors Agonist")
The American Society of Clinical Oncology (ASCO) is one of the largest and most respected conferences in the field of oncology. Held annually, this conference brings together researchers, physicians, and other healthcare professionals from around the world to discuss the latest advances in cancer research, diagnosis, and treatment.
